231 related articles for article (PubMed ID: 34910297)
21. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
23. Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.
Dechaphunkul T; Arundon T; Raungkhajon P; Jiratrachu R; Geater SL; Dechaphunkul A
Clin Nutr; 2022 Feb; 41(2):433-440. PubMed ID: 35007812
[TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
25. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yin Y; Zhou Z; Li Z; Shen M; Qin Y; Yang C; Wang R; Kang M
Radiat Oncol; 2022 Jul; 17(1):135. PubMed ID: 35906636
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
30. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
33. [Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
Bi T; Jin F; Wu W; Long J; Li Y; Gong X; Luo X; Li Z; He Q; Qu B
Zhonghua Zhong Liu Za Zhi; 2015 Sep; 37(9):676-81. PubMed ID: 26813432
[TBL] [Abstract][Full Text] [Related]
34. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
35. A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.
Yang G; Feng D; Li F; Luo B; Zhu J; Yang Q; Zheng L; Dong Q; Chen M; Xu Z; Li L; Chen P; Sun J
Radiother Oncol; 2021 Oct; 163():76-82. PubMed ID: 34343545
[TBL] [Abstract][Full Text] [Related]
36. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Chen Q; Tang L; Liu N; Han F; Guo L; Guo S; Wang J; Liu H; Ye Y; Zhang L; Liu L; Wang P; Li Y; He Q; Yang X; Tang Q; Li Y; Liang Y; Sun X; Xie C; Mo Y; Guo Y; Sun R; Mo H; Cao K; Guo X; Zeng M; Mai H; Ma J
Cancer Commun (Lond); 2018 Nov; 38(1):66. PubMed ID: 30382933
[TBL] [Abstract][Full Text] [Related]
37. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
39. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Zhang L; Qu X; Teng Y; Shi J; Yu P; Sun T; Wang J; Zhu Z; Zhang X; Zhao M; Liu J; Jin B; Luo Y; Teng Z; Dong Y; Wen F; An Y; Yuan C; Chen T; Zhou L; Chen Y; Zhang J; Wang Z; Qu J; Jin F; Zhang J; Jin X; Xie X; Wang J; Man L; Fu L; Liu Y
J Clin Oncol; 2017 Nov; 35(31):3558-3565. PubMed ID: 28854065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]